Hu, X., Xu, J., Wang, W., Liu, L., Jing, Y., Gao, C., Yu, X., Li, Y., Lin, L., Tong, J., Weng, Q., Pan, X., Zhang, W., Ren, H., Li, G., Kiryluk, K., Chen, N., & Xie, J. (2024). Combined Serologic and Genetic Risk Score and Prognostication of Phospholipase A2 receptor-Associated Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 19(5), 573–582. https://doi.org/10.2215/cjn.0000000000000422

Marchel, D., Trachtman, H., Larkina, M., Helmuth, M., Lai Yee, J. Y., Fermin, D., Bomback, A. S., Canetta, P. A., Gipson, D. S., Mottl, A. K., Parekh, R. S., Saha, M. K., Sampson, M. G., Lafayette, R. A., & Mariani, L. H. (2023). The Significance of Hematuria in Podocytopathies. Clinical Journal of the American Society of Nephrology, 19(1), 56–66. https://doi.org/10.2215/cjn.0000000000000309

Sethi, S., Beck, L. H., Glassock, R. J., Haas, M., De Vriese, A. S., Caza, T. N., Hoxha, E., Lambeau, G., Tomas, N. M., Madden, B., Debiec, H., D’Agati, V. D., Alexander, M. P., Amer, H., Appel, G. B., Barbour, S. J., Caravaca-Fontan, F., Cattran, D. C., Casal Moura, M., … Fervenza, F. C. (2023). Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification. Mayo Clinic Proceedings, 98(11), 1671–1684. https://doi.org/10.1016/j.mayocp.2023.08.006

Sethi, S., Beck, L. H., Glassock, R. J., Haas, M., De Vriese, A. S., Caza, T. N., Hoxha, E., Lambeau, G., Tomas, N. M., Madden, B., Debiec, H., D’Agati, V. D., Alexander, M. P., Amer, H., Appel, G. B., Barbour, S. J., Caravaca-Fontan, F., Cattran, D. C., Casal Moura, M., … Fervenza, F. C. (2023). Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney International, 104(6), 1092–1102. https://doi.org/10.1016/j.kint.2023.06.032

Barbour, S. J., Fervenza, F. C., Induruwage, D., Brenchley, P. E., Rovin, B., Hladunewich, M. A., Reich, H. N., Lafayette, R., Aslam, N., Appel, G. B., Zand, L., Kiryluk, K., Liu, L., & Cattran, D. C. (2023). Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 18(10), 1283–1293. https://doi.org/10.2215/cjn.0000000000000237

Okabayashi, Y., Tsuboi, N., Marumoto, H., Sasaki, T., Haruhara, K., Kanzaki, G., Koike, K., Ueda, H., Shimizu, A., Puelles, V. G., D’Agati, V., & Yokoo, T. (2023). Single-Nephron GFR in Different Glomerular Basement Membrane Stages of Membranous Nephropathy. Kidney360, 4(6), e777–e786. https://doi.org/10.34067/kid.0000000000000142

Oliva-Damaso, N., & Bomback, A. S. (2021). Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO. Kidney360, 2(11), 1696–1698. https://doi.org/10.34067/kid.0001842021

Peleg, Y., Bomback, A. S., Canetta, P. A., Radhakrishnan, J., Appel, G. B., & Ahn, W. (2021). Late Relapses of Membranous Nephropathy: A Case Series. Kidney360, 2(6), 974–982. https://doi.org/10.34067/kid.0007712020